Clear leader
9 companies value 37 bn revenue 7.1 bn margin 19.9% free cash flow 1.6 bn avg. score 2.2
RMD holds 93.0% of the group's value, 17.1x the runner-up
| Rank | Ticker | Company | Share | Value | Revenue | Margin | FCF | 5 years | FCF/px | Yield | What it does · why it is here |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RMD | ResMed United States · score 7.2 | 93% | 35 bn | 5.7 bn | 26.9% | 1.6 bn | 4.8% | 1.0% | CPAP devices and digital health for sleep apnea · Global leader in sleep apnea devices (CPAP) | |
| 2 | INSP | Inspire Medical Systems United States · score 6.0 | 6% | 2.0 bn | 0.9 bn | 15.0% | 0.1 bn | 5.8% | — | Implant for obstructive sleep apnea · Implant that treats sleep apnea without a mask; a growing alternative | |
| 3 | INGN | Inogen Inc United States · score 0.4 | 1% | 0.2 bn | 0.3 bn | -6.9% | 0.0 bn | -2.9% | — | Respiratory health medical technology · Massachusetts — revenue of $354m | |
| 4 | ELMD | Electromed, Inc. United States · score 5.4 | 1% | 0.2 bn | 0.1 bn | 15.3% | 0.0 bn | 3.7% | — | Airway clearance devices · Minnesota — revenue of $74m | |
| 5 | LUNG | Pulmonx Corp United States · score 0.0 | 0% | 0.1 bn | 0.1 bn | -55.0% | -0.0 bn | -40.8% | — | Minimally invasive medical technology for severe emphysema · California — revenue of $87m | |
| 6 | NYXH | Nyxoah SA Belgium · score 0.0 | 0% | 0.1 bn | 0.0 bn | -443.2% | -0.1 bn | -86.1% | — | Implant for obstructive sleep apnea, from Belgium · Belgium — revenue of $24m | |
| 7 | XAIR | Beyond Air, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -435.7% | -0.0 bn | -979.9% | — | Nitric oxide generators and delivery systems · New York — revenue of $8m | |
| 8 | VVOS | Vivos Therapeutics, Inc. United States · score 0.0 | — | — | 0.0 bn | -121.8% | -0.0 bn | — | — | Oral appliances for obstructive sleep apnea · Colorado — revenue of $21m | |
| 9 | QTEX | QTREX Quantum Ltd. Israel · score 0.5 | — | — | 0.0 bn | -847.9% | -0.0 bn | — | — | Respiratory medical technology, from Israel · Israel — revenue of $2m |
Other industries in the same sector
- Sector overview
- Large-cap pharmaceuticals 9 companies
- Biotechnology 57 companies
- European pharmaceuticals 5 companies
- Lab tools and consumables 37 companies
- Health insurance and services 17 companies
- Medical devices 87 companies
- Specialty pharmaceuticals 77 companies
- Pharmaceutical distribution 7 companies
- Clinical-stage pharmaceuticals 251 companies
- Robotic surgery and advanced medtech 9 companies
- Hospitals 23 companies
- Emerging biotech 5 companies
and 22 industries more
- Molecular testing and advanced diagnostics 42 companies
- Vaccines and mRNA 14 companies
- Clinical-stage biotech 200 companies
- Generics and biosimilars 10 companies
- Animal health 7 companies
- Contract research (CRO) 10 companies
- Consumer health (OTC) 4 companies
- Healthcare software 18 companies
- Rehabilitation and home care 15 companies
- Genomics and sequencing 9 companies
- Structural heart 8 companies
- Ophthalmology 12 companies
- Medical imaging and hospital equipment 16 companies
- Diagnostic labs 6 companies
- Medical and dental supply distribution 3 companies
- Diabetes monitoring 9 companies
- Pharmaceutical royalties 5 companies
- Orthopedic implants 17 companies
- Dialysis 3 companies
- Telehealth and digital health 12 companies
- Dental 4 companies
- Medical and recreational cannabis 16 companies
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.